SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio-Chem Pharma (BCHXF)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jbershad who wrote (24)8/20/1996 12:00:00 PM
From: Constant Reader   of 43
 
Jerry:

Yesterday, I talked with a physician who deals with these drugs and patients every day. One example of the efficacy of 3TC: patient is 10+ years asymptomatic. Used AZT alone years ago. CD4 count gradually declined from base of 900+ to 500 range. Viral RNA count about 10 months ago: 11,000. AZT/3TC combination ALONE has had results of 700 average T-cell count, Viral RNA count less than 800!

I think that is a fantastic result, and bodes well for 3TC.

Re: Protease Inhibitors (PI's): AGPH is in final stage of clinical trials and should have approval about October. Thus far, it has shown the fewest side-effects of any PI: loose stools apparently most common. PI's already on market have higher indices of more severe side-effects.

BTW, take a look at a company called MDLI: they are writing the software these drug companies are all using to develop these new drugs and are one reason that 4-5 companies came out with similar drugs at same time. Take care,

Randy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News